Stocksigma LogoStocksigma Logo

3B BlackBio Dx Reports H1'27 Performance and Growth Strategy

In H1'27, 3B BlackBio Dx posted consolidated revenue of ₹8,177.10 lakh, up 45.7% YoY, with PAT at ₹2,700.17 lakh and EPS of ₹31.51

3B BlackBio Dx Reports H1'27 Performance and Growth Strategy

3B BlackBio Dx Ltd · Investor Presentation · 13 Nov 2026, 9:45 pm

3B BlackBio Dx Reports H1'27 Performance and Growth Strategy In H1'27, 3B BlackBio Dx posted consolidated revenue of ₹8,177.10 lakh, up 45.7% YoY, with PAT at ₹2,700.17 lakh and EPS of ₹31.51. Excluding Coris, revenue reached ₹6,413.72 lakh and PAT climbed 16.4% YoY to ₹3,269.49 lakh. The company holds a ~15% share in India's ₹500–600 Cr molecular diagnostics market and targets 15–20% growth in FY'27. Coris reduced H1 EBITDA losses by 45% and secured a €1.41M HAT order for delivery in Dec'26, while 3B pursues targeted M&A opportunities in the US.

Original exchange filing (PDF)

More announcements from 3B BlackBio Dx Ltd

All 3B BlackBio Dx Ltd announcements